Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA
Authors:
- Zofia MazerskaZofia Mazerska
- Jaroslaw DziegielewskiJDJaroslaw Dziegielewski
- Jerzy KonopaJKJerzy Konopa
- 1 March 2001
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 61 (6) , 685-694
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311British Journal of Cancer, 1999
- The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivativesChemico-Biological Interactions, 1998
- C-1311Drugs of the Future, 1998
- Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancerBritish Journal of Cancer, 1996
- Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbationBritish Journal of Cancer, 1996
- Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cellsCancer Chemotherapy and Pharmacology, 1996
- Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemiasJournal of Medicinal Chemistry, 1992
- Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acidsBiochemical Pharmacology, 1989
- Myeloperoxidase: a myeloid cell nuclear antigen with DNA-binding properties.Proceedings of the National Academy of Sciences, 1988
- DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalatorsNucleic Acids Research, 1987